Publication type
Journal Article
Authors
- Sander W. van der Laan
- Tove Fall
- Aicha Soumaré
- Alexander Teumer
- Sanaz Sedaghat
- Jens Baumert
- Delilah Zabaneh
- Jessica van Setten
- Ivana Isgum
- Tessel E. Galesloot
- Johannes Arpegård
- Philippe Amouyel
- Stella Trompet
- Melanie Waldenberger
- Marcus Dörr
- Patrik K. Magnusson
- Vilmantas Giedraitis
- Anders Larsson
- Andrew P. Morris
- Janine F. Felix
- Alanna C. Morrison
- Nora Franceschini
- Joshua C. Bis
- Maryam Kavousi
- Christopher O'Donnell
- Fotios Drenos
- Vinicius Tragante
- Patricia B. Munroe
- Rainer Malik
- Martin Dichgans
- Bradford B. Worrall
- Jeanette Erdmann
- Christopher P. Nelson
- Nilesh J. Samani
- Heribert Schunkert
- Jonathan Marchini
- Riyaz S. Patel
- Aroon D. Hingorani
- Lars Lind
- Nancy L. Pedersen
- Jacqueline de Graaf
- Lambertus A. L. M. Kiemeney
- Sebastian E. Baumeister
- Oscar H. Franco
- Albert Hofman
- André G. Uitterlinden
- Wolfgang Koenig
- Christa Meisinger
- Annette Peters
- Barbara Thorand
- J. Wouter Jukema
- Bjørn Odvar Eriksen
- Ingrid Toft
- Tom Wilsgaard
- N. Charlotte Onland-Moret
- Yvonne T. van der Schouw
- Stéphanie Debette
- Meena Kumari
- Per Svensson
- Pim van der Harst
- Mika Kivimaki
- Brendan J. Keating
- Naveed Sattar
- Abbas Dehghan
- Alex P. Reiner
- Erik Ingelsson
- Hester M. den Ruijter
- Paul I. W. de Bakker
- Gerard Pasterkamp
- Johan Ärnlöv
- Michael V. Holmes
- Folkert W. Asselbergs
Publication date
August 15, 2016
Summary:
Background: Epidemiological studies show that high circulating cystatin C is associated with risk of cardiovascular disease (CVD), independent of creatinine-based renal function measurements. It is unclear whether this relationship is causal, arises from residual confounding, and/or is a consequence of reverse causation. Objectives: The aim of this study was to use Mendelian randomization to investigate whether cystatin C is causally related to CVD in the general population. Methods: We incorporated participant data from 16 prospective cohorts (n = 76,481) with 37,126 measures of cystatin C and added genetic data from 43 studies (n = 252,216) with 63,292 CVD events. We used the common variant rs911119 in CST3 as an instrumental variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, ischemic stroke, and heart failure. Results: Cystatin C concentrations were associated with CVD risk after adjusting for age, sex, and traditional risk factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence interval [CI]: 1.56 to 2.13; p = 2.12 × 10−14). The minor allele of rs911119 was associated with decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p = 5.95 × 10−211), explaining 2.8% of the observed variation in cystatin C. Mendelian randomization analysis did not provide evidence for a causal role of cystatin C, with a causal relative risk for CVD of 1.00 per doubling cystatin C (95% CI: 0.82 to 1.22; p = 0.994), which was statistically different from the observational estimate (p = 1.6 × 10−5). A causal effect of cystatin C was not detected for any individual component of CVD. Conclusions: Mendelian randomization analyses did not support a causal role of cystatin C in the etiology of CVD. As such, therapeutics targeted at lowering circulating cystatin C are unlikely to be effective in preventing CVD.
Published in
Journal of the American College of Cardiology
Volume and page numbers
Volume: 68 , p.934 -945
DOI
http://dx.doi.org/10.1016/j.jacc.2016.05.092
ISSN
7351097
Subjects
Notes
Open Access article
Under a Creative Commons license
#523890